Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Applied DNA Schedules Fiscal 2019 Third Quarter Financial Results Conference Call for Tuesday, August 13, 2019 at 4:30 PM ET
August 06, 2019 05:00 AM Eastern Daylight Time
STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN), announced today it plans to release financial results for its fiscal 2019 third quarter ended June 30, 2019 after market close on Tuesday, August 13, 2019. In conjunction with the release, the Company has scheduled a conference call at 4:30 p.m. Eastern Time that will also be broadcast live over the Internet.
What:
Applied DNA’s Fiscal 2019 Third Quarter Financial Results Conference Call
When:
Tuesday, August 13, 2019, at 4:30 p.m. Eastern Time
Where:
Via phone by dialing +1 844-887-9402 or +1 412-317-6798 and ask to join the Applied DNA call; via webcast.
A telephonic replay of the conference call will be available for one day and may be accessed by calling +1 877-344-7529 or +1 412-317-0088 with the passcode 10133063. The webcast will be archived within the ‘Events and Presentations’ portion of the ‘Investors’ page to the company’s website.
About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and pre-clinical nucleic acid-based therapeutic drug candidates.
Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
Common stock listed on NASDAQ under the symbol ‘APDN’ and warrants are listed under the symbol ‘APDNW’.
Forward Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its ability to repay the Notes if not converted, history of net losses, limited financial resources, limited market acceptance, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.
Contacts
Investors: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Web: www.adnas.com
Twitter: @APDN
APPLIED DNA SCIENCES, INC.
NASDAQ:APDN View stock quote and chart View SEC Filings
More NewsRSS feed for Applied DNA Sciences, Inc.
Log InSign Up
More from Business Wire
BlogAppsUK/IrelandDeutschlandFranceHong KongItalyJapanTradeshownews.com
And Nasdaq still does not have it on their list.
Which means, I believe, it isn’t scheduled in the near future for any form of action.
Another mystery wrapped in an enigma.
Hayward is full of ‘em.
There is a Nasdaq pending delisting site.
APDN is not on there. Also , the notification is not there.
Very strange.
Well, one thing seems obvious if you can apply logic to any of this.
APDN must have had a successful hearing with Nasdaq.
Otherwise ? It is 8/8/2019 according to my calendar
Shark, I pasted the whole paper
revolutionizing nucleic acid-based therapies with linear DNA
LineaRxTM
LRxTM revolutionizing nucleic acid-based therapies with linear DNA
Linear DNA Substitution for Plasmid DNA
Despite great strides in gene therapy, both the safety and efficacy of nucleic acid vectors need to be improved, and the cost and time associated with their manufacture must be reduced in order to realize their full clinical potential. The demand for gram-scale DNA and RNA continues to increase and is most frequently provided from plasmids obtained via bacterial fermentation. Plasmid systems are far from optimized for safety and efficacy, and despite material cost and time-to-manufacture issues they remain the most common form of manufactured DNA, central both to the production of the target therapeutic reading frames, and the viral vectors used in the majority of gene and cell therapies.
LineaRx (LRx), a wholly-owned subsidiary of Applied DNA Sciences, believes linear DNA manufactured via PCR offers unique attributes including the ability to chemically modify linear DNA, the absence of bacterial and plasmid contaminants and a non-recombinant approach to gene therapy. The benefits that will inure these attributes will increase patient safety, therapeutic efficacy, ease regulatory burdens associated with gene therapies, and provide significant cost and time advantages to produce gene and cell therapies.
The LineaRx PCR over Plasmid DNA Production Advantage
Benefits of Linear DNA
LineaRx (LRx) has an exclusive license for core technologies (through Applied DNA Sciences) related to very large-scale linear DNA manufacture by Polymerase Chain Reaction (PCR). The key to the LRx’s unique role in pharmaceutics is its ability to produce gene-sized fragments at gram scale that are completely devoid of bacterial or plasmid DNA, mitogen or other kinds of protein contamination that would arise from a bacterial DNA source, thus greatly reducing the regulatory risks associated with the use of DNA in gene therapy.
LRx solves these plasmid problems by using large-scale PCR to create a low-cost product in a format that allows for exploration beyond traditional methods of DNA/RNA production, amplification, and delivery. Non- target bacterial or plasmid gene consequences are eliminated. Additionally, DNA end-modifications introduced during PCR allow for increased cellular uptake, expression, episomal persistence, longevity and separation into single strands.
©2019 Applied DNA Sciences, Inc. - ver1 2
LRxTM revolutionizing nucleic acid-based therapies with linear DNA
A significant secondary attribute of the LRx technology is its ability to introduce, within one or both PCR
primers, modifications to the ends of an LRx amplicon to confer useful functional properties, such as:
• DNA sequences that can fold upon themselves to form non-duplex structures such as a G-quadruplex;
• Present custom designed poly A tails; or,
• Present chemical linkages (e.g., amines, carboxylates, thiols) that are suitable for bio-conjugate chemistry.
Such terminal modifications to an LRx amplicon also serve as an effective way to block the principle exonuclease activity in the cell, thus increasing cellular DNA stability prior to expression.
To that base, LRx has filed patents to protect newly-developed design principles, allowing for enhanced polypeptide production when using linear LRx amplicons. Additional work is underway to enable direct delivery of the LRx constructs into cells via non-viral methods, with special emphasis on prompt permeabilization of cultured cells for transfection. Preliminary work with one of our partners suggests that such chemical permeabilization is highly efficient for LRx linear amplicons, and could facilitate use of the technologies for both clinical application (as in CAR-T Therapy), and as a new way to enable the production of therapeutic recombinant virus (lentivirus, recombinant Adeno-Associated Virus (rAAV)) via plasmid-free assembly.
We anticipate that any transgene can be delivered as a linear DNA, and we believe linear amplicons as large as 10kb or greater are achievable through our manufacturing approach. Thus far, our experience is with linear amplicons less than 5kb, including anti-CD19 CAR-T and proprietary linear amplicons prepared for customers as part of our ongoing CRO (Contract Research Organization) business.
Reduced Risk of Antibiotic Resistance Transfer
The mobile genetic elements within bacterial and plasmid DNA conflate the entire gene pool of the bacterial kingdoms, effectively yielding a single pool from which individual bacteria can draw genes that facilitate their survival in the face of harsh environments, such as in the presence of antibiotics. It is this mechanism for the promiscuous transference of antibiotic resistance that generates the resistant strains threatening global health.1
Plasmids may contain a variety of mobile, off-target and detrimental sequences: antibiotic-selectable markers, prokaryotic origins of replication, sequences that trigger immune responses and sequences that have genotoxic effects near the insertion site.2 Fermentation increases the risk of bacterial endotoxins and worsening inflammatory side-effects such as Cytokine Release Syndrome (CRS.)
While commercial plasmids have been refined to decrease these risks, the potential for negative consequences has not been fully eliminated. In their “Guidance for Industry, Final Version, Recommendations for Microbial Vectors used for Gene Therapy,” FDA required antibiotic testing3, making it clear that risk of transferring antibiotic resistance to the genome of the patient, along with other off-target plasmid sequences, remains a regulatory concern.
LineaRx as a Contract Research and Contract Manufacturing Organization (CRO/CMO)
Since the founding of LineaRx in October 2018, best-in-class pharmaceutical and biotechnology companies have sought LRx’s expertise and production methods, seeking alternatives to bacterial plasmid DNA and viral delivery. That work has entailed the development of low-cost, large-scale production of customer’s existing DNA constructs in the fields of adoptive cell therapy, RNA therapeutics, gene therapy and in-vitro diagnostics.
©2019 Applied DNA Sciences, Inc. - ver1 3
LRxTM revolutionizing nucleic acid-based therapies with linear DNA LineaRx Commercialization Strategy for Linear DNA
The CRO/CMO function of LRx is the cornerstone of the business, and we are investing in its development to continue to grow and deliver recurring, reliable revenue to the LRx bottom line. More than 12 customers and research partners have been served over the past year, and over 10,000 mg of custom DNA/RNA product have been delivered, much of which contains proprietary modifications developed by the LRx team. We do expect that the LRx CMO business will soon be providing product produced under cGMP (current Good Manufacturing Practices.) Revenues scale as customers mature from CRO toward CMO, eventually entering the clinic and commercial supply. LRx is in a unique position to service long-term supply needs for commercial scale nucleic acids.
The primary PCR product is double-stranded. We have developed methods to isolate individual strands thereafter. It is possible to functionally modify the oligos that make up the 5’ end of each strand. We have other chemical processes that can add function to both the 3’ and 5’ ends of the dsDNA. We can attach the dsDNA or ssDNA versions to beads and chemical moieties.
Plasmid templates are used in most cases at LRx, at least at present, in that such plasmids have already been designed and put into use by our customers seeking linear DNA as a replacement. We, however, use fully- synthetic “Synthetic Genetics” DNA templates, at roughly 100/year, in our ongoing diagnostics and tagging businesses within the Applied DNA Sciences parent company, and will deploy such longer synthetic gene constructs for our DNA therapy business at LRx, as needed. We have the ability to design large genes of that kind without a template. The assembled gene content, which we call high expression amplicons (HEAs, patent- pending) can be transduced into cell therapies chemically or as part of a viral carrier. In this manner PCR products may be manufactured without a trace of plasmid DNA.
Fabrication of a purely synthetic silicon genetics-derived template takes about 2 weeks, using the same contractor who has been supplying synthetic DNA constructs in support of our DNA diagnostics and tagging businesses. The next step in the process is PCR primer design, which has become a technology that we have streamlined on both synthetic and plasmid-based templates. Once a new template is obtained (either synthetic or plasmid), a small number of PCR primer pairs is designed, chemically synthesized and tested with the new template, via a process which has been reduced to about 2 weeks. Once the PCR optimization is completed, small batch scale PCR manufacture and confirmation of DNA purification methodology is performed, which may take another week. Thus, the total ramp-up takes about 5 weeks, from sequence data info to small-scale manufacture. In general, we have the capacity to run 2-3 such ramp-up activities simultaneously. Once ramp- up is complete, large-scale DNA quantities can be produced very rapidly.
LineaRx DNA Substitution for Plasmid DNA
Vaccines
CRO Preclinical
CMO Clinical & Commercial
Strategic Alliances
Proprietary Therapeutics
Fee-for-Service Out License IP
Supply Agreements Out License IP
Drug Out License LDNA Supply Agreement
DNA Therapies
RNA Therapies
Virus Production
Redirected Cell Therapies
©2019 Applied DNA Sciences, Inc. - ver1
4
LRxTM revolutionizing nucleic acid-based therapies with linear DNA
The go-to-market service strategy guiding LRx ensures a growing revenue base with recurring customers, and steady exposure to the evolving sciences that contribute to genetic therapies. LRx expects that a select number of service clients will utilize LRx Intellectual Property (IP.) Such licensing agreements may take the form of long- term agreements or strategic investments in LRx. As of July 2019, we are currently engaged with several companies in this type of dialogue.
Proprietary LRx Therapeutics
One of the greatest contributors to shareholder value for LRx will come from proprietary therapeutics. We expect to develop our proprietary therapeutics initially through pre-clinical phase, usually without sponsors. Partners will be sought as our developments mature toward clinical trials.
Strategic Partnerships and Licenses
Takis/Evvivax SRL
LineaRx and Takis/Evvivax SRL (spun out of Merck) are collaborating on the development of a PCR-DNA- based cancer vaccine for delivery in human and veterinary contexts by means of electroporation. Significant levels of linear LRx DNA vaccine expression have been recorded in cells and in an animal model, thus establishing the viability of LRx linear DNA as the basis for a cancer vaccine. LineaRx believes the results of this study will help set precedent that PCR amplified linear DNA can become the standard for effective, low- cost DNA-based vaccines. These promising results prompted a joint development agreement. Under the agreement with Evvivax and its parent company Takis, two cancer vaccines are being developed. The first is for companion animals and the second is a personalized neoantigen-based vaccine for humans. Both projects are in pre-clinical mouse studies with the possibility of a dog trial starting later this year. Both parties are interested in soliciting funding for the clinical trial and go-to-market.
Anti-CD19b CAR T Adoptive Cell Therapy
The field of immunotherapy has witnessed a breakthrough in recent years based on Chimeric Antigenic Receptor (CAR) T- Cell Therapy. Two FDA approved CAR-T therapies show immediate clinical benefit. However, their hefty price tag (one dose costs ~$500,000) and burdensome manufacturing process suggest that the technology in its current form will never be available to a broad patient population. This substantial cost and demanding production process is largely attributed to utilization of standard bacterial plasmid amplification, then viral encapsulation/transduction model. That approach is not only costly but may also contain hidden dangers due to the intrinsic risk of using a human virus to deliver a drug, including insertional oncogenesis. LineaRx has licensed an Anti-CD19b CAR-T construct from iCell Therapeutics, Inc. The viral implementation of the Anti-CD19b drug is currently being tested (in its plasmid + virus form) in clinical trials in China and has already shown remarkable performance and safety in the clinic. LineaRx has developed a linear form of iCell’s Anti-CD19b (appropriately named linCD19CAR) and will be publishing a parallel set of preclinical studies with linCD19CAR in the near future.
This license will not only serve in the LRx long-term vision but will also benefit its CRO/CMO business in attracting customers in the field of CAR-T and related immuno-oncology therapies.
Proprietary Modifications to the CAR-T Process
Personalization of CAR-T - The current methodology used to produce a CAR-T Therapy in viruses is not only cost-prohibitive, it is also slow and non-personalized. Plasmid DNA must be introduced into and amplified in bacteria, then removed from the bacteria, purified, and subsequently encapsulated into a viral carrier via a lengthy and expensive process that entails complex steps and requires approximately 30 days
©2019 Applied DNA Sciences, Inc. - ver1 5
LRxTM revolutionizing nucleic acid-based therapies with linear DNA
to produce. Such viral-based production must be performed before the patient is even known. Though this may work for select cancers with predetermined markers, a personalized therapy is impossible in this model.
PCR-amplified DNA, delivered non-virally, could very well be a personalized medicine game-changer, with 1) an individual’s blood and cancer sampled/analyzed; 2) a respective T-cell binding region generated; 3) a DNA sequence generated and amplified; 4) DNA introduced into the patients T-cells; 5) T-cells injected back into the patient. All of these steps utilize cGMP robotics located within the hospital.
High-Expression Amplicon - LineaRx has not only licensed the iCell Anti-CD19 construct, but has developed pending patents which teach how to amplify the expression of linear DNA. That technology, referred to as the LineaRx HEA (High-Expression Amplicon), contains a multitude of enhancements to increase expression and mitigate linear DNA manufacturing error.
This microscope image above is of human T Cells grown in primary culture. The image was derived 24 hours after modification by electroporation with a Linear DNA Amplicon produced, designed and manufactured via LRx PCR technology.
This linear DNA amplicon contains the complete gene which encodes production of Green Fluorescent Protein (GFP). The microscope image is of that green fluorescence generated from the synthesis of GFP protein in the cell. Each cell which has taken up the linear amplicon in a functional form is converted to a 10mm diameter green cell. Expression is greater than 30%, with more than 90% of the cells surviving. We see expression for at least 8 days. We are developing methods to obtain linear DNA (episomal) replication over 10-20 cell divisions, but this work is in an early stage.
As is obvious from the microscope image, hundreds of such T Cells have taken up the Linear GFP Amplicon, thus generating a “constellation” of green fluorescent cells in the micrograph.
To our knowledge, these are the first data to demonstrate the uptake and subsequent gene expression of a PCR-generated gene fragment in human T Cells facilitated by commercially scalable high-throughput electroporation.
©2019 Applied DNA Sciences, Inc. - ver1 6
LRxTM revolutionizing nucleic acid-based therapies with linear DNA
Linear HEA produced AAV for rapid therapeutic strategy
The gene and cell therapy market projects tighter controls by FDA on microbial and viral vectors used for gene therapy to ensure delivery of products that are safe and free of bacterial contaminants. With the advent of cell therapies initially using lentivirus, it has become clear that production of these retroviral therapies will be expensive, complex and difficult. Plasmids pose a risk in that these bacterially derived genes and pieces of DNA can lead to gene cytotoxicity and antigenicity if they are integrated accidently as a result of therapies produced using these vectors.
A process using production of PCR-amplified expression amplicons for AAV manufacture can be carried out to eliminate these plasmid safety risks. Additionally, the ease and rapid production of PCR amplicons are safer and are directed to one spot in the cell with great efficiency and precision using high efficiency production of rep and cap genes immediately and throughout the 100-hour production window. LRx HEA amplicons can be used for production with far less plasmid than the conventional process. These linear HEAs are then used to produce RNA and DNA for rapid identification of the selected set required for linear DNA transfection into HEK293 cells to remove all plasmid contaminants as well as to enter safely into the patient's cells without fear of off-site targeting.
With the use of highly optimized linear DNA for the AAV helper and Ad5 helper plasmids, a sophisticated process of engineering a linear DNA HEA amplicon quickly for the payload plasmid has been worked out by LineaRx. This optimized set of three linear pieces of DNA can provide large-scale production of AAV therapeutics in less than 100 hours. The process will allow for a custom set for each client resulting in specific tropism for the disease indication being pursued. The resulting virus production can be performed in high throughput for selection of only positive strand DNA containing AAV sequences boosting therapeutic efficiency on target tissues.
The process for virion production and ex vivo transduction of T cells, NK cells, or iPCS can be accomplished rapidly and with high integration rates. The system is incorporated into the LineaRx platform for selection of mitigated positive strand therapeutic AAV virion particles for highest rates of transduction seen to date. When coupled with the LRx engager platform, the most useful AAV targeting for disease site for therapeutic dispersal is possible. The AAV virion can be targeted specifically for a cell surface receptor bringing the payload to the cell being targeted.
CRISPR requires delivery of a DNA payload by chemical or viral transfection. The LRx manufacturing technology can support the chemical transfection of such CRISPR payloads into target cells. Additionally, we have recently reduced to practice (we believe for the first time) the ability to create double strand linear DNA payload for rAAV production that includes the left and right viral iTR to deliver an open reading frame to support the delivery of CRISPR cargo and we propose, a wide range of DNA therapeutics in a way that replaces the use of plasmid DNA.
Patents
We own a US and international patent on devices for large scale PCR and have filed two additional patents (pending) on the use of large-scale PCR to generate linear templates for biotherapeutics. Due to our ongoing gram-scale PCR-based manufacturing expertise, already in place to support our diagnostics and tagging businesses, we have an unequaled portfolio of trade secrets in support of such very large-scale PCR design and manufacture. We are not aware of any other company or academic lab in the US or internationally with that combination of patent and trade secret IP to enable therapeutics scale PCR.
©2019 Applied DNA Sciences, Inc. - ver1 7
LRxTM revolutionizing nucleic acid-based therapies with linear DNA
Patent Portfolio
Exclusive worldwide license from Applied DNA Sciences empowering PCR-based production of DNA (amplicons) for nucleic acid-based therapies:
• Provides exclusive ability to produce gene-sized amplicons via PCR at tremendous scale • Broad licensed rights: patents held in US, FR, DE, IT, UK, IE, JP, AUS, CN, CA, HK, and ISR • Pending global IP for use of PCR-produced amplicons in engineered lymphocyte cells
References
- IP covers use of PCR-produced amplicons for: CAR T-cell therapy, TCR T-cell therapy, in vivo antibody/antigen production and other redirected lymphocyte therapies
- Contains novel PCR error mitigation production methodologies
- US and international patent applications filed
• Filed in US under USPTO immunotherapy pilot program – preferential treatment
• Interest from major immunotherapy biotech players
- Pending IP for use of PCR-produced amplicons for DNA-based vaccines
• IP developed with Evvivax S.R.L and Takis S.R.L.
• Covers PCR-produced DNA vaccines for cancer (anti-TERT, neoantigens) and viruses • US application filed
- Pending IP for rAAV manufacture via PCR produced amplicons
1. Bennet, P.M., “Plasmid encoded antibiotic resistance: acquisition and transfer of antibiotic resistance genes in bacterial,” Br. J. Pharmacol., 2008 Mar, 153 (Suppl 1): S347-S357.
2. Nafissi, N., Alqawlaq, S., Lee, E.A., Foldvari, M., Spagnuolo, P.A., ands Slavcev, R.A., “DNA Ministrings: Highly Safe and Effective Gene Delivery Vectors,” Mol. Therapy – Nucl. Acids, 2014, 3, e165
3.“Recommendations for Microbial Vectors used for Gene Therapy, Guidance for Industry,”
https://www.fda.gov/media/94200/download, Sept. 2016
LineaRxTM
james.hayward@adnas.com | +1 631.240.8801 | linearxdna.com 50 Health Sciences Drive | Stony Brook, New York 11790 USA
©2019 Applied DNA Sciences, Inc. - ver1
8
I got a pdf emailed from Brian:
Director, Product Management
LineaRx, Inc.
50 Health Sciences Drive
Stony Brook, NY 11790
Office +1 (631) 240-8877
Brian.Viscount@adnas.com
If you contact him he’ll email you the White Paper. I don’t think I can copy and paste the whole paper
Patent Portfolio
Exclusive worldwide license from Applied DNA Sciences empowering PCR-based production of DNA (amplicons) for nucleic acid-based therapies:
• Provides exclusive ability to produce gene-sized amplicons via PCR at tremendous scale • Broad licensed rights: patents held in US, FR, DE, IT, UK, IE, JP, AUS, CN, CA, HK, and ISR • Pending global IP for use of PCR-produced amplicons in engineered lymphocyte cells
References
- IP covers use of PCR-produced amplicons for: CAR T-cell therapy, TCR T-cell therapy, in vivo antibody/antigen production and other redirected lymphocyte therapies
- Contains novel PCR error mitigation production methodologies
- US and international patent applications filed
• Filed in US under USPTO immunotherapy pilot program – preferential treatment
• Interest from major immunotherapy biotech players
- Pending IP for use of PCR-produced amplicons for DNA-based vaccines
• IP developed with Evvivax S.R.L and Takis S.R.L.
• Covers PCR-produced DNA vaccines for cancer (anti-TERT, neoantigens) and viruses • US application filed
- Pending IP for rAAV manufacture via PCR produced amplicons
From the white paper just filed:
Patents
We own a US and international patent on devices for large scale PCR and have filed two additional patents (pending) on the use of large-scale PCR to generate linear templates for biotherapeutics. Due to our ongoing gram-scale PCR-based manufacturing expertise, already in place to support our diagnostics and tagging businesses, we have an unequaled portfolio of trade secrets in support of such very large-scale PCR design and manufacture. We are not aware of any other company or academic lab in the US or internationally with that combination of patent and trade secret IP to enable therapeutics scale PCR.
Regardless of all that. Once again we don’t know the details of the convertible nature of the preferred stock or the note.
We also don’t know when and if TX is going to list Theracan.
The reverse merger is with a company that has a halt on its trading.
Sooo, to be the Devils advocate here, I’m guessing the Theracan stock will be a gold mine.
Everything’s a positive if you’re laying in the gutter.
I agree. And this requested meeting should be detailed as to when it was requested.
This 11th hour crap has to end.
The problem with a reverse split is that they rarely work.
The underlying financials quarter after quarter keep getting worse, not better.
I assume this quarter will be even more dire.
A company in a continuously declining position will not be able to make a reverse split work.
If the situation had been different with improving financials, it might have been an option.
They have requested a hearing already.
This traditionally takes another 6 months.
Been down this road before with several stocks.
Hayward better have some big aces up his sleeve.
Why would anyone care of it’s OTC if they want to own it?
It is probably automatic stop loss sales plus calls to stockholders with leveraged positions. Takes about 24 hrs for those triggers to happen.
So, they’re doing balance sheet compliance.
Cotton, Colorcon, ACG, Theracan, fertilizers, and I forget what else.
This is a three year track record that takes first place in continual and unending quarterly disappointments.
The last quarter was half the revenue of 4 years ago.
There would have to be something so magnanimous from Hayward at this point that it would dwarf the Ascension.
If Theracan has defaulted on its payment, then the agreement is voided, as it would appear.
My research shows that the suspended trading was requested pending significant news.
Right, because of the exclusive clientele these pens would attract, it doesn’t seem we are talking about large volume.
And what is Beacon® Ink??
Apparently registered by APDN.
Anyone ever hear of this ink.??
These pens will be ver expensive for exclusive clientele:
“This Agreement culminates a rigorous 18-month product development and qualification program between Applied DNA and Montblanc for SigNature DNA with Beacon® in a range of specialist inks for use in the high-end range of Montblanc writing instruments. The SigNature DNA molecular tag provides the forensic evidence for traceability; Beacon is a covert screening feature of the SigNature DNA molecular tag, fluorescing only with complementary decryptant.”
It sounds to me like these are specific pens for some very important people and their documents.
If they are able to authenticate that a signature was made by a specific pen, it means the ink is marked to the specific pen used.
This also means each pen and its ink will each need a unique marker.
Not meant for the general public.
I contacted Sanjay over 6 months ago. He said the deal was in process. Then in February you contacted him I believe.
So, how long was the ACG MOU for. Don’t these have a time limit.??
Also Colorcon. Wasn’t a revelation due last March???
It looks like TruTrace raised about 20 million USD on the IPO.
88 million shares float right out the gate.
Well, if TruTrace and Etch Biotrace are in the beginnings of being partnered for supply chain/ product security it can only be good.
TruTrace needs to buy or consolidate with APDN to complete the circle.
It has a post date of late June 2019.
Go figure?
Did we ever see this article on the details of the Gujarat lab???
https://adnas.com/central-dna-testing-laboratory/
Well, of course. Doesn’t APDN paid staff do all of this research??
The only instance where they didn’t would be government/military marking programs.
I find this section of the PLOS ONE published paper to be very interesting:
“In an experiment designed to test a proprietary method of distinguishing legitimate pharmaceuticals from counterfeit products, including imitation opioids, a pharma manufacturer tagged acetaminophen capsules with “pharmaceutical-grade ink” containing Applied DNA’s SigNature molecular tags.
The study not only proved that the DNA-based molecular tags could be safely introduced to ordinary pharmaceutical ink, but that authentication of the tags – via handheld portable devices – could be “performed reliably” in the field, according to “Rapid authentication of pharmaceuticals via DNA tagging and field detection,” published in PLOS ONE’s June 2019 edition.”
I wonder which pharma ran the tests??
I believe the CBD oil via Singapore will dwarf Israel and Canada.
Szechwan province can grow it all year long outdoors.
It will look like a bamboo forest.
Hayward only has to file a paper explaining how he plans to revalue the pps.
Believe me , the six month extension is a formality.
Get calm.
Thanks Rode. I think there is a tie-in with MIT with Mike Hogan.
Wouldn’t be surprised if we are supplying them with engineered DNA
Well, you can ask yourself , why such large minimum payments?
It seems to me they are based on anticipated joy juice, tagging and tracing revenues.
It is also quite high for guaranteed minimums.
Those minimums might be reached by China CBD oil alone. Look at the presages.
I notice from their website and PRs, they have operations, agreemeoin the following:
Canada
USA
Panama
Columbia
South Africa
Australia
China
Germany
Spain
Morocco
Uruguay
Well, this is the reverse merger I was talking about some time ago.
The company to have bought was Trusted Brands at 40 cents CAD on the TSX.
Who knew??
A lot of interesting info here also:
http://www.yarnsandfibers.com/news/news-tags/pima-cotton
Jennifer Marks
New Egyptian Cotton committee to oversee branding
Will steer licensing and promotion
Jennifer Marks, December 24, 2018
Cairo, Egypt – The Egyptian government has created an official steering committee to safeguard the future of the Egyptian Cotton brand.
The new committee is made up of government and trade representatives has been appointed by the Minister of Trade & Industry. It will be responsible for the licensing and promotion of Egyptian Cotton globally and will police the integrity of the supply chain to ensure full compliance, traceability and transparency.
Egyptian cotton
The Cotton Egypt Association (CEA), which until now has had sole responsibility for licensing and promoting the luxury cotton brand, has been incorporated into the new structure.
Khaled Schuman, executive director of CEA and head of the newly formed Egyptian Cotton Logo Unit, said: “I am proud to be a member of the new steering committee, which will build on the work already carried out by the CEA to promote Egyptian Cotton globally, protect the supply chain and ensure the welfare of the workers."
The full make-up of the new steering committee will include: two members from The Ministry of Trade & Industry; two members from the Alexandria Cotton Exporters Association (ALCOTEXA); two members from Cotton Egypt Association (CEA); one member from the Holding Company for Cotton, Spinning, Weaving & RMG; one from the Ministry of Agriculture and one from the High Council of Textiles.
Mr Schuman added: “The creation of this strong steering committee reflects The Egyptian Government’s strong will to make a real reform in the Egyptian Cotton’s supply chain.”
The brand has been rebuilding since 2011 when output fell drastically – following political upheaval.
“Despite the setbacks, Egyptian Cotton is still widely recognised by the consumer as a luxury brand and a recent US consumer survey found Egyptian Cotton was the name most people associated with quality and were prepared to pay a premium for, ahead of Pima cotton, Turkish cotton and Supima,” the committee said in a statement.
Initiatives to improve confidence in the Egyptian Cotton logo include the introduction of a partnership with Bureau Veritas and a new rigorous accreditation process, which uses DNA testing to distinguish between genuine Egyptian Cotton and regular cotton.